Core Insights - Elicio Therapeutics has appointed Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer, bringing extensive leadership experience from previous roles in biotechnology companies [1][2][3] Company Overview - Elicio Therapeutics is a clinical-stage biotechnology company focused on developing novel immunotherapies for cancer treatment, particularly targeting high-prevalence cancers such as mKRAS-positive pancreatic and colorectal cancers [4] - The company aims to leverage its Amphiphile ("AMP") technology to enhance the education, activation, and amplification of cancer-specific T cells, promoting durable cancer immunosurveillance [4][8] Product Pipeline - Elicio's lead product candidate, ELI-002, is an off-the-shelf vaccine targeting common KRAS mutations, which are responsible for approximately 25% of all solid tumors [4][7] - ELI-002 is currently being studied in a Phase 1/2 clinical trial (AMPLIFY-7P) for patients with mKRAS-positive pancreatic cancer who are at high risk of relapse [7] - The company also has additional candidates in its pipeline, including ELI-007 and ELI-008, targeting BRAF-driven cancers and p53 hotspot mutations, respectively [4] Technology Platform - The AMP platform is designed to deliver immunotherapeutics directly to lymph nodes, enhancing immune responses and potentially leading to more effective cancer treatments [8][10] - Elicio's technology has shown promise in preclinical models, indicating that lymph node-specific engagement can drive stronger and more durable therapeutic immune responses [10]
Elicio Therapeutics Appoints Preetam Shah, Ph.D., MBA, as Chief Strategy and Financial Officer